Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12647368 | 0.96 | TBXAS1 (0.49) | STK17BSTK17ATBXAS1TDP1MEN1 | |
| SCHEMBL6585454 | 0.95 | TDP1 (0.51) | STK17BSTK17ATBXAS1TDP1MEN1 | |
| SCHEMBL4713820 | 0.92 | NPSR1 (0.47) | STK17BSTK17ATBXAS1TDP1NAMPT | |
| SCHEMBL3794186 | 0.83 | L3MBTL1 (0.48) | STK17BSTK17ATDP1NAMPTL3MBTL1 | |
| SCHEMBL2780861 | 0.80 | TBXAS1 (0.54) | TBXAS1NAMPT | |
| SCHEMBL22039513 | 0.79 | TDP1 (0.44) | STK17BSTK17ATDP1MEN1KMT2A | |
| SCHEMBL24306044 | 0.78 | TBXAS1 (0.50) | TBXAS1NAMPTPOLB | |
| SCHEMBL4242018 | 0.78 | FDPS (0.41) | STK17BSTK17ATBXAS1TDP1L3MBTL1 | |
| SCHEMBL3845409 | 0.78 | MEN1 (0.42) | STK17BSTK17ATDP1MEN1KMT2A | |
| SCHEMBL24872799 | 0.78 | MEN1 (0.45) | STK17BSTK17ATDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008067222-A1 | HETEROCYCLIC MODULATORS OF TGR5 | KALYPSYS, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-6740661-B2 | TRICYCLIC IMINE CONTAINING COMPOUNDS HAVING IMIDAZOLE SUBSTITUENT; ANTITUMOR AGENTS | SCHERING CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-20020103207-A1 | Farnesyl protein transferase inhibitors | TAVERAS ARTHUR G (US) | 2002-08-01 | — | — | US | disclosed |
| US-6372747-B1 | ENZYME INHIBITORS AND ANTICARCINOGENIC AGENTS | SCHERING CORPORATION | 2002-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | STK17B 2606/4885STK17A 2129/4885TBXAS1 1517/4885 |
| US-20020103207-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, ACAT2 | STK17B 2645/4885STK17A 1990/4885TBXAS1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.